Disparities in Biopsy Practice in Metastatic Breast Cancer Patients Managed in Community Oncology Practices in the United States: Implications for Guideline-Concordant Care [0.03%]
美国社区肿瘤实践机构中转移性乳腺癌患者的活检实践差异及其对指南一致性的意义
George Dranitsaris,Heather Neuhalfen,Nik Seifter et al.
George Dranitsaris et al.
Objectives: The National Comprehensive Cancer Network guidelines recommend tumor phenotyping for estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 at initial breast cancer diagnosis, w...
Immunotherapy in Extensive Stage Small-Cell Lung Cancer in First-Line and Second-Line: A Systematic Review and Meta-Analysis [0.03%]
广泛期小细胞肺癌一线和二线免疫治疗的系统评价和 meta 分析
Nupur Krishnan,Patsy Lee,Gabriel Boldt et al.
Nupur Krishnan et al.
Objectives: Despite a good response to first-line chemotherapy, small-cell lung cancer (SCLC) has high relapse rates and a poor prognosis. We conducted a systematic review and meta-analysis to assess the role of immune ch...
Targeted and Chemo-Free Approaches in HER2-Positive Early Breast Cancer: A Systematic Review and Meta-Analysis [0.03%]
HER2阳性早期乳腺癌的靶向及无化疗策略：系统评价和 meta 分析
Zaheer Qureshi,Abdur Jamil,Navkirat Kahlon et al.
Zaheer Qureshi et al.
Objectives: Human epidermal growth factor receptor-2 (HER2)-positive breast cancer is rapidly growing with poor outcomes if left untreated. Research evidence indicates that chemotherapy-free regimens can improve outcomes ...
A Real-World, Propensity-Matched Analysis of Second-Line FOLFIRI-Ramucirumab Versus Ramucirumab-Paclitaxel in Patients With Advanced Upper Gastrointestinal Cancers [0.03%]
真实世界中的倾向匹配分析：二线FOLFIRI-ramucirumab与ramucirumab-紫杉醇治疗晚期上消化道癌症患者的疗效对比研究
Jonathan M Hyak,Peifeng Ruan,Amy L Jones et al.
Jonathan M Hyak et al.
Objectives: There is an urgent need for effective second line treatments for advanced upper gastrointestinal (UGI) cancers. Ramucirumab and paclitaxel (Ram-Pac) has long been the standard therapy; however, this regimen is...
Impact of Interruptions in Chemotherapy on Survival for Patients With Metastatic or Recurrent Cervical Cancer [0.03%]
化疗中断对转移性或复发性宫颈癌患者生存率的影响
Risha Sinha,Arianna Portmann-Baracco,April R Gorman et al.
Risha Sinha et al.
Objectives: Chemotherapy interruptions are a frequent event during treatment of solid tumors and have been associated with adverse survival outcomes. Our objective was to determine the impact of intercycle delay during fi...
Development and Validation of Palmitoylation-Related Genes in the Prognostic and Immunologic Characterization of Lung Adenocarcinoma [0.03%]
棕榈酰化相关基因在肺癌腺癌预后和免疫特征表征中的发展与验证
Pingjing Li,Yun Xiong
Pingjing Li
Objectives: Lung adenocarcinoma (LUAD), which is the most frequently diagnosed form of lung cancer, constitutes a major global health challenge due to its significant mortality rate. Palmitoylation, as a key post-translat...
Riddhi R Patel,Jonathan Feit,Grace Werling et al.
Riddhi R Patel et al.
Objectives: Synovial sarcoma (SS) of the abdomen and pelvis is a rare and understudied condition. This study aimed to evaluate survival outcomes, assess calculated versus observed outcomes, and describe radiographic featu...
Binsah George,Manu Pandey,Jacob Herstein et al.
Binsah George et al.
Acute myeloid leukemia (AML) continues to pose a major hurdle in hematologic oncology, driven by its genetic complexity and tendency to resist standard therapies. Even with progress in treatment-such as high-dose chemotherapy and hematopoie...
Targeting Tumor-Induced Immune Disorder: A New Frontier in Cancer Immunotherapy [0.03%]
针对肿瘤诱导的免疫紊乱：癌症免疫治疗的新前沿
Lingbing Zhang,Xun Zhu
Lingbing Zhang
Risk Model Based On Neutrophil-Related Genes Constructs to Assess Prognosis and Immune Landscape in Diffuse Large B-Cell Lymphoma [0.03%]
基于中性粒细胞相关基因的风险模型构建评估弥漫大B细胞淋巴瘤的预后和免疫图谱
Xinfang Gao,Xinguo Luo,Hongwei Ye et al.
Xinfang Gao et al.
Objectives: Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, represents a highly heterogeneous cancer. Neutrophils, as the core effector cells of intrinsic immunity, play an important r...